what a great resolution for shareholders!

http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=00993433

Quote: ITEM 4: ADOPTION OF REMUNERATION REPORT
The Company's Remuneration Report is set out in pages 16 to 23 of the Company's 2009 Annual Report. The Remuneration Report:
�� Explains the Company's policy and processes for determining the remuneration of its senior executives;
�� Discusses the relationship between remuneration policy and the Company's performance; and
�� Sets out remuneration details of each Director and each key executive with the greatest authority for the strategic direction and management of the Company.

The F2009 cash incentive payment will be made in August 2009, once approved by the Board.
The cash incentive is capped as a percentage of TFR for each individual. The CEO’s limit is 60%, the limit for other key management personnel is 40%, with progressively lower amounts for other members of staff.

Senior executives, generally the key management personnel, are allocated rights to Biota shares which vest when
pre-set Total Shareholder Return (TSR) conditions are achieved.

The tables above are a summary of the shares allocated in F2009 and the TSR targets for each performance
measure at 30 June 2011.
Threshold : $1.06
Target : $1.12
Stretch: $1.31

The Board has determined that the final TSR measure will comprise 80% of the absolute component and 20% of the relative component...... . End of Quote

BTA shareholders, last year despite shareholders voting down the resolution rewarding Peter Cook 456,000 free options for selling out the GSK law suit, Peter Cook collected his 456,000 free options and announced it to the ASX on 19 Dec 2008 thinking shareholders are too busy celebrating Xmas to notice his windfall.

Your CEO and BTA management are smarter and bolder this year. Instead of voting for specific resolution spelling out their greed, they have asked shareholders to vote for the “Adoption of Remuneration Report” for which Quote”The F2009 cash incentive payment will be made in August 2009, once approved by the Board.”

This is as dishonest as it gets – on 30 September 2009, your directors KEPT you in the dark on the incentives the board had ALREADY APPROVED and PAID in August 2009 and ask you to approve it in default by approving the remuneration report. Or perhaps I am confused by the mumbo-jumbo : they may have approved and paid the 60% incentives to Peter Cook and 40% for the other executives?

Look at the wonderful “Stretch Target Share Price on 30 June 2011 of $1.31” the Directors want shareholders to approve.

Is this why Peter Cook is so determined to talk down the share price? Last year Peter Cook was rewarded for refusing to accept the $100m GSK offer and then after spending $30m in legals costs Peter Cook settled for $20m.

This year Peter Cook is to be rewarded for praising GSK's
performance where:
1) Despite Tamiflu problems, Roche sold 1.1 billion of Tamiflu for the 6 months to June compared to $584.5 million

2) Roche planned to increase Tamiflu production to 400 million dozes by 1 Jan 10 and announced last month they had achieved this. In comparison, GSK planed to increase production to 190million by 1 Jan 10 and Peter Cook announced in late August – Quote: assume GSK’s capacity can be built as planned

3) The post by 202020 in September had the Japanese health authorities’ figures showing that Tamiflu had again captured 90% of the market compare to 10% for Relenza because Tamiflu Quote “is more widely available than Relenza”.

BTA share holders will be over the moon with joy for the BTA sp to be $1.31 on 30 June 2011...LOL